Humalog solution for injection

Pajjiż: Armenja

Lingwa: Ingliż

Sors: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredjent attiv:

insulin lispro

Disponibbli minn:

Lilly France S.A.S.

Kodiċi ATC:

A10AB04

INN (Isem Internazzjonali):

insulin lispro

Dożaġġ:

100IU/ml (3,5mg/ml)

Għamla farmaċewtika:

solution for injection

Unitajiet fil-pakkett:

(5) cartridges 3ml

Tip ta 'preskrizzjoni:

Prescription

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2016-08-23

Fuljett ta 'informazzjoni

HUMALOG
*
100 U/ML SOLUTION FOR INJECTION IN CARTRIDGE
INSULIN LISPRO (RDNA ORIGIN)
1.
NAME OF THE MEDICINAL PRODUCT
Humalog 100 U/ml, solution for injection in cartridge
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1 GENERAL DESCRIPTION
Humalog is a sterile, clear, colourless, aqueous solution.
2.2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One
ml
contains
100U
(equivalent
to
3.5mg)
insulin
lispro
(recombinant
DNA
origin
produced
in
E.coli).
Each container includes 3ml equivalent to 300U insulin lispro.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the treatment of adults and children with diabetes mellitus who
require insulin for the maintenance of normal
glucose homeostasis. Humalog is also indicated for the initial
stabilisation of diabetes mellitus.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The dosage should be determined by the physician, according to the
requirement of the patient.
Humalog
may
be
given
shortly
before
meals.
When
necessary
Humalog
can
be
given
soon
after
meals.
Humalog preparations should be given by subcutaneous injection or by
continuous subcutaneous infusion pump
(see section 4.2) and may, although not recommended, also be given by
intramuscular injection. If necessary,
Humalog may also be administered intravenously, for example; for the
control of blood glucose levels during
ketoacidosis, acute illnesses or during intra and post operative
periods.
Subcutaneous administration should be in the upper arms, thighs,
buttocks, or abdomen. Use of injection sites should
be rotated so that the same site is not used more than approximately
once a month.
When administered subcutaneously care should be taken when injecting
Humalog to ensure that a blood vessel has
not been entered. After injection, the site of injection should not be
massaged. Patients must be educated to use the
proper injection techniques.
Humalog takes effect rapidly and has a shorter duration of activity (2
to 5 hours) given

Karatteristiċi tal-prodott

_1 _
_ _
1. NAME OF THE MEDICINAL PRODUCT
Humalog 100 U/ml, solution for injection in cartridge
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1 GENERAL DESCRIPTION
Humalog is a sterile, clear, colourless, aqueous solution.
2.2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains 100U (equivalent to 3.5mg) insulin lispro (recombinant
DNA origin produced in E.coli).
Each container includes 3ml equivalent to 300U insulin lispro.
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Solution for injection.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the treatment of adults and children with diabetes mellitus who
require insulin for the maintenance of
normal glucose homeostasis. Humalog is also indicated for the initial
stabilisation of diabetes mellitus.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The dosage should be determined by the physician, according to the
requirement of the patient.
Humalog may be given shortly before meals. When necessary Humalog can
be given soon after meals.
Humalog preparations should be given by subcutaneous injection or by
continuous subcutaneous infusion
pump (see section 4.2) and may, although not recommended, also be
given by intramuscular injection. If
necessary, Humalog may also be administered intravenously, for
example; for the control of blood glucose
levels during ketoacidosis, acute illnesses or during intra and post
operative periods.
Subcutaneous administration should be in the upper arms, thighs,
buttocks, or abdomen. Use of injection sites
should be rotated so that the same site is not used more than
approximately once a month.
When administered subcutaneously care should be taken when injecting
Humalog to ensure that a blood
vessel has not been entered. After injection, the site of injection
should not be massaged. Patients must be
educated to use the proper injection techniques.
Humalog takes effect rapidly and has a shorter duration of activity (2
to 5 hours) given subcutaneously as
compared with regular insulin. This rapid onset of activi